(Q37725909)

22 August 2017

Fingolimod after natalizumab and the risk of short-term relapse (English)

1 reference

22 August 2017

22

Helmut Butzkueven

1 reference

22 August 2017

21

Danny Liew

1 reference

22 August 2017

4

Guillermo Izquierdo

1 reference

22 August 2017

9

Pierre Duquette

1 reference

22 August 2017

6

Raed Alroughani

1 reference

22 August 2017

Vilija G Jokubaitis

1

1 reference

22 August 2017

Vivien Li

2

1 reference

22 August 2017

Tomas Kalincik

3

1 reference

22 August 2017

Suzanne Hodgkinson

5

1 reference

22 August 2017

Jeannette Lechner-Scott

7

1 reference

22 August 2017

Alessandra Lugaresi

8

1 reference

22 August 2017

Marc Girard

10

1 reference

22 August 2017

Michael Barnett

11

1 reference

22 August 2017

Francois Grand'Maison

12

1 reference

22 August 2017

Maria Trojano

13

1 reference

22 August 2017

Mark Slee

14

1 reference

22 August 2017

Giorgio Giuliani

15

1 reference

22 August 2017

Cameron Shaw

16

1 reference

22 August 2017

Cavit Boz

17

1 reference

22 August 2017

Daniele L A Spitaleri

18

1 reference

22 August 2017

Freek Verheul

19

1 reference

22 August 2017

Jodi Haartsen

20

1 reference

22 August 2017

MSBase Study Group

23

1 reference

22 August 2017

language of work or name

English

0 references

publication date

7 March 2014

1 reference

22 August 2017

1 reference

22 August 2017

82

1 reference

22 August 2017

14

1 reference

22 August 2017

1204-1211

1 reference

How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

Oral fingolimod (FTY720) for relapsing multiple sclerosis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

Clinical pharmacokinetics of fingolimod

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

Fingolimod for the treatment of relapsing multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

Reduction of the washout time between natalizumab and fingolimod.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

Tumefactive multiple sclerosis lesions under fingolimod treatment.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

Immune surveillance in multiple sclerosis patients treated with natalizumab.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

Predictors of relapse rate in MS clinical trials.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

A controlled trial of natalizumab for relapsing multiple sclerosis.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4001200

Severe relapses under fingolimod treatment prescribed after natalizumab

1 September 2018

1 reference

12 December 2020

Switching from natalizumab to fingolimod: an observational study

1 reference

12 December 2020

Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy

1 reference

12 December 2020

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

1 reference

12 December 2020

Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients

1 reference

12 December 2020

Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients

1 reference

12 December 2020

Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration

1 reference

12 December 2020

10.1212/WNL.0000000000000283

Identifiers

DOI

1 reference

22 August 2017

1 reference

22 August 2017

PubMed publication ID

24610329

1 reference